Mathematical modeling as accounting: Predicting the fate of serum proteins and therapeutic monoclonal antibodies

被引:9
|
作者
Gurbaxani, Brian [1 ]
机构
[1] Ctr Dis Control & Prevent, Viral Exanthems & Herpes Virus Branch, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA
关键词
FcRn; albumin; antibodies; half life; mathematical modeling;
D O I
10.1016/j.clim.2006.10.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This article reviews current efforts to mathematically model the half lives of serum proteins, especially antibodies. While it is recognized that the neonatal Fc receptor, FcRn, is necessary for longer serum persistence of certain proteins, particularly the high abundance IgGs and albumin, it is not clear that it is sufficient to completely determine the half lives of these proteins. More specifically, it is unclear why the high avidity (bivalent), high affinity FcRn-IgG interaction, with half saturation in the 10 to 100 nM range (at endosomal pH according to the currently proposed mechanism), would result in a salvage mechanism that saturates at serum concentrations in the 10 to 100 mg/ml range a discrepancy of 4 to 5 orders of magnitude. Alternative explanations include the proposal that the very tow affinity binding between FcRn and IgG at blood pH is also relevant to the salvage mechanism, and that factors in addition to FcRn binding modulate the maintenance and clearance of IgG from serum. Published by Elsevier Inc.
引用
收藏
页码:121 / 124
页数:4
相关论文
共 50 条
  • [21] Mathematical modeling of plaque progression and associated microenvironment: How far from predicting the fate of atherosclerosis?
    Cai, Yan
    Li, Zhiyong
    COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2021, 211
  • [22] Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution
    Milewski, Mikolaj
    Murashov, Mikhail
    Kapoor, Yash
    Zhang, Jingtao
    Zhu, Wei
    Cueto, Maria A.
    Buist, Nicole
    MOLECULAR PHARMACEUTICS, 2024, 21 (10) : 4947 - 4959
  • [23] Optimization and mathematical modeling of the transtubular bioreactor for the production of monoclonal antibodies from a hybridoma cell line
    Halberstadt C.R.
    Palsson B.O.
    Midgley A.R.
    Curl R.L.
    Biotechnology and Bioprocess Engineering, 2002, 7 (3) : 163 - 170
  • [24] Toward a Suite of Coarse-Grained Models for Molecular Simulation of Monoclonal Antibodies and Therapeutic Proteins
    Shahfar, Hassan
    Forder, James K.
    Roberts, Christopher J.
    JOURNAL OF PHYSICAL CHEMISTRY B, 2021, 125 (14): : 3574 - 3588
  • [25] Impact of Urea on Monoclonal Antibodies: Multiple Destabilization and Aggregation Effects for Therapeutic Immunoglobulin G Proteins
    Yang, Ji Young
    Burkert, Oliver
    Mizaikoff, Boris
    Smiatek, Jens
    ACS OMEGA, 2024, 9 (05): : 5517 - 5522
  • [26] Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum
    Bee, Christine
    Abdiche, Yasmina N.
    Pons, Jaume
    Rajpal, Arvind
    PLOS ONE, 2013, 8 (11):
  • [27] Polyneuropathies associated with high titre antisulphatide antibodies: Characteristics of patients with and without serum monoclonal proteins
    Lopate, G
    Parks, BJ
    Goldstein, JM
    Yee, WC
    Friesenhahn, GM
    Pestronk, A
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (06): : 581 - 585
  • [28] A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum
    Wala, Iwona
    Swanson, Steven J.
    Jing, Shuqian
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 45 (04) : 583 - 589
  • [29] A Review of Methodologies for the Detection, Quantitation, and Localization of Free Cysteine in Recombinant Proteins: A Focus on Therapeutic Monoclonal Antibodies
    Metcalfe, Clive
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [30] Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues
    Ziemssen, Focke
    Sobolewska, Bianka
    Deissler, Heidrun
    Deissler, Helmut
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (01) : 75 - 87